Collagen Prolyl Hydroxylases Are Bifunctional Growth Regulators in Melanoma.


Journal

The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720

Informations de publication

Date de publication:
05 2019
Historique:
received: 16 09 2017
revised: 24 09 2018
accepted: 01 10 2018
pubmed: 20 11 2018
medline: 8 5 2020
entrez: 20 11 2018
Statut: ppublish

Résumé

Appropriate post-translational processing of collagen requires prolyl hydroxylation, catalyzed by collagen prolyl 3-hydroxylase and collagen prolyl 4-hydroxylase, and is essential for normal cell function. Here we have investigated the expression, transcriptional regulation, and function of the collagen prolyl 3-hydroxylase and collagen prolyl 4-hydroxylase families in melanoma. We show that the collagen prolyl 3-hydroxylase family exemplified by Leprel1 and Leprel2 is subject to methylation-dependent transcriptional silencing in primary and metastatic melanoma consistent with a tumor suppressor function. In contrast, although there is transcriptional silencing of P4HA3 in a subset of melanomas, the collagen prolyl 4-hydroxylase family members P4HA1, P4HA2, and P4HA3 are often overexpressed in melanoma, expression being prognostic of worse clinical outcomes. Consistent with tumor suppressor function, ectopic expression of Leprel1 and Leprel2 inhibits melanoma proliferation, whereas P4HA2 and P4HA3 increase proliferation, and particularly invasiveness, of melanoma cells. Pharmacological inhibition with multiple selective collagen prolyl 4-hydroxylase inhibitors reduces proliferation and inhibits invasiveness of melanoma cells. Together, our data identify the collagen prolyl 3-hydroxylase and collagen prolyl 4-hydroxylase families as potentially important regulators of melanoma growth and invasiveness and suggest that selective inhibition of collagen prolyl 4-hydroxylase is an attractive strategy to reduce the invasive properties of melanoma cells.

Identifiants

pubmed: 30452903
pii: S0022-202X(18)32822-7
doi: 10.1016/j.jid.2018.10.038
pmc: PMC7015666
mid: NIHMS1068465
pii:
doi:

Substances chimiques

Collagen 9007-34-5
Prolyl Hydroxylases EC 1.14.11.-
Procollagen-Proline Dioxygenase EC 1.14.11.2
P3H2 protein, human EC 1.14.11.7

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1118-1126

Subventions

Organisme : NIAMS NIH HHS
ID : R01 AR044276
Pays : United States
Organisme : Medical Research Council
Pays : United Kingdom
Organisme : Chief Scientist Office
Pays : United Kingdom
Organisme : Cancer Research UK
Pays : United Kingdom

Informations de copyright

Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Références

J Med Chem. 2018 Dec 13;61(23):10403-10411
pubmed: 29986141
Br J Cancer. 2012 Oct 9;107(8):1423-32
pubmed: 22955849
Br J Cancer. 2009 May 19;100(10):1687-96
pubmed: 19436308
Oncotarget. 2015 May 20;6(14):12297-309
pubmed: 25909218
Cell. 2006 Mar 24;124(6):1283-98
pubmed: 16564017
Clin Cancer Res. 2009 Mar 1;15(5):1801-7
pubmed: 19223509
J Invest Dermatol. 2013 May;133(5):1278-85
pubmed: 23407390
ACS Chem Biol. 2016 Jan 15;11(1):193-9
pubmed: 26535807
Eur J Biochem. 2001 Oct;268(20):5300-9
pubmed: 11606192
J Cell Biol. 1998 Jul 27;142(2):587-94
pubmed: 9679154
J Biol Chem. 2011 Sep 2;286(35):30662-9
pubmed: 21757687
BMC Cancer. 2014 Jan 02;14:1
pubmed: 24383403
Annu Rev Biochem. 2009;78:929-58
pubmed: 19344236
Nat Cell Biol. 2013 Jun;15(6):677-87
pubmed: 23644467
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
Future Oncol. 2017 Aug;13(20):1755-1766
pubmed: 28587477
Br J Cancer. 2012 Apr 10;106(8):1446-52
pubmed: 22454080
Genes Dev. 2012 Sep 15;26(18):2038-49
pubmed: 22925884
Ann Med. 2008;40(6):402-17
pubmed: 19160570
Crit Rev Biochem Mol Biol. 2010 Apr;45(2):106-24
pubmed: 20199358
Science. 2006 Aug 18;313(5789):968-71
pubmed: 16917063
BMC Med. 2008 Apr 28;6:11
pubmed: 18442412
Circulation. 2003 Aug 5;108(5):508-11
pubmed: 12874193
Cancer Res. 2013 Jun 1;73(11):3285-96
pubmed: 23539444

Auteurs

Aithne Atkinson (A)

John Fulcher Brain Tumour Research Laboratory, Imperial College, Hammersmith Hospital, London, UK.

Alexander Renziehausen (A)

John Fulcher Brain Tumour Research Laboratory, Imperial College, Hammersmith Hospital, London, UK.

Hexiao Wang (H)

Department of Dermatology, The First Hospital of China Medical University, Shenyang, China.

Cristiana Lo Nigro (C)

Laboratory of Cancer Genetics and Translational Oncology, S. Croce General Hospital, Cuneo, Italy.

Laura Lattanzio (L)

Laboratory of Cancer Genetics and Translational Oncology, S. Croce General Hospital, Cuneo, Italy.

Marco Merlano (M)

Laboratory of Cancer Genetics and Translational Oncology, S. Croce General Hospital, Cuneo, Italy.

Bhavya Rao (B)

Dundee Cancer Centre, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.

Lynda Weir (L)

Dundee Cancer Centre, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.

Alan Evans (A)

Department of Pathology, Ninewells Hospital, Dundee, UK.

Rubeta Matin (R)

Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Imperial College London, London, UK.

Catherine Harwood (C)

Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Imperial College London, London, UK.

Peter Szlosarek (P)

Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Imperial College London, London, UK.

J Geoffrey Pickering (JG)

Robarts Research Institute, Western University, London, Ontario, Canada.

Colin Fleming (C)

Department of Dermatology, Ninewells Hospital, Dundee, UK.

Van Ren Sim (VR)

Kent Oncology Centre, Maidstone Hospital, Maidstone, UK.

Su Li (S)

Royal Marsden Hospital, Fulham Road, London, UK.

James T Vasta (JT)

Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA.

Ronald T Raines (RT)

Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

Mathieu Boniol (M)

International Prevention Research Institute, Lyon, France.

Alastair Thompson (A)

MD Anderson Cancer Center, Houston, Texas, USA.

Charlotte Proby (C)

Dundee Cancer Centre, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK; Department of Dermatology, Ninewells Hospital, Dundee, UK.

Tim Crook (T)

Department of Oncology, St Luke's Cancer Centre, Royal Surrey County Hospital, Guilford, UK. Electronic address: timothycrook@nhs.net.

Nelofer Syed (N)

John Fulcher Brain Tumour Research Laboratory, Imperial College, Hammersmith Hospital, London, UK. Electronic address: n.syed@imperial.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH